Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz


| Molecular Weight | 552.6 g/mol |
|---|---|
| Molecular Formula | C26H22F2N6O4S |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 10 |
| Rotatable Bond Count | 3 |
| Exact Mass | 552.13913070 g/mol |
| Monoisotopic Mass | 552.13913070 g/mol |
| Topological Polar Surface Area | 147 A^2 |
| Heavy Atom Count | 39 |
| Formal Charge | 0 |
| Complexity | 1030 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 2 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
Details:
Talazoparib Tosylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Lead Product(s): Talazoparib Tosylate,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 16, 2021

Lead Product(s) : Talazoparib Tosylate,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer
Details : Talazoparib Tosylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 16, 2021

Details:
Trifluridine is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Lead Product(s): Trifluridine,Tipiracil HCl,Talazoparib Tosylate
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Cytotoxic Drug
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 12, 2020

Lead Product(s) : Trifluridine,Tipiracil HCl,Talazoparib Tosylate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Trifluridine is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
August 12, 2020

Details:
Gemtuzumab Ozogamicin is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.
Lead Product(s): Ozogamicin,Talazoparib,Talazoparib Tosylate
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody-drug Conjugate
Sponsor: Pfizer Inc
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 20, 2019

Lead Product(s) : Ozogamicin,Talazoparib,Talazoparib Tosylate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Pfizer Inc
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gemtuzumab Ozogamicin is a Antibody-drug Conjugate drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
December 20, 2019

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Talazoparib Tosylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Lead Product(s): Talazoparib Tosylate,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Miscellaneous
Sponsor: Melinda Telli
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 27, 2015

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Talazoparib Tosylate,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Melinda Telli
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Talazoparib Tosylate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 27, 2015

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Marketed
Registration Country : Norway
Brand Name : Talzenna
Dosage Form : Capsule
Dosage Strength : 0.25mg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Marketed
Registration Country : Norway

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Marketed
Registration Country : Norway
Brand Name : Talzenna
Dosage Form : Capsule
Dosage Strength : 1mg
Packaging :
Approval Date :
Application Number :
Regulatory Info : Marketed
Registration Country : Norway

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Talzenna
Dosage Form : Hard Capsule
Dosage Strength : 1MG
Packaging :
Approval Date : 11-09-2019
Application Number : 1191377005
Regulatory Info : Authorized
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Authorized
Registration Country : Spain
Brand Name : Talzenna
Dosage Form : Hard Capsule
Dosage Strength : 0.1MG
Packaging :
Approval Date : 15-01-2024
Application Number : 191377007
Regulatory Info : Authorized
Registration Country : Spain

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Talzenna
Dosage Form : Hard Capsules
Dosage Strength : 0.1mg
Packaging :
Approval Date : 05-01-2024
Application Number : 28106916023
Regulatory Info : Prescription
Registration Country : Denmark

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Talzenna
Dosage Form : Hard Capsules
Dosage Strength : 0.25mg
Packaging :
Approval Date : 20-06-2019
Application Number : 28106121818
Regulatory Info : Prescription
Registration Country : Denmark

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Prescription
Registration Country : Denmark
Brand Name : Talzenna
Dosage Form : Hard Capsules
Dosage Strength :
Packaging :
Approval Date : 20-06-2019
Application Number : 28106121918
Regulatory Info : Prescription
Registration Country : Denmark

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Talzenna
Dosage Form : Capsule
Dosage Strength : 0.25mg
Packaging :
Approval Date : 20-06-2019
Application Number : 2.02E+13
Regulatory Info : Approved
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Talzenna
Dosage Form : Capsule
Dosage Strength :
Packaging :
Approval Date : 20-06-2019
Application Number : 2.02E+13
Regulatory Info : Approved
Registration Country : Sweden

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : Approved
Registration Country : Sweden
Brand Name : Talzenna
Dosage Form : Capsule
Dosage Strength : 0.35mg
Packaging :
Approval Date : 20-06-2025
Application Number : 2.02E+13
Regulatory Info : Approved
Registration Country : Sweden

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : PRESCRIPTION
Registration Country : Canada
TALAZOPARIB (TALAZOPARIB TOSYLATE)
Brand Name : TALZENNA
Dosage Form : CAPSULE
Dosage Strength : 0.25MG
Packaging :
Approval Date :
Application Number : 2492032
Regulatory Info : PRESCRIPTION
Registration Country : Canada

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Regulatory Info : PRESCRIPTION
Registration Country : Canada
TALAZOPARIB (TALAZOPARIB TOSYLATE)
Brand Name : TALZENNA
Dosage Form : CAPSULE
Dosage Strength : 0.1MG
Packaging :
Approval Date :
Application Number : 2555050
Regulatory Info : PRESCRIPTION
Registration Country : Canada

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Global Sales Information
Company : Pfizer US Pharm
Talazoparib Tosylate
Drug Cost (USD) : 14,816,664
Year : 2023
Prescribers : 234
Prescriptions : 878

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Pfizer US Pharm
Talazoparib Tosylate
Drug Cost (USD) : 6,401,237
Year : 2022
Prescribers : 81
Prescriptions : 430

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Pfizer US Pharm
Talazoparib Tosylate
Drug Cost (USD) : 7,758,691
Year : 2021
Prescribers : 106
Prescriptions : 553

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Pfizer US Pharm
Talazoparib Tosylate
Drug Cost (USD) : 8,270,787
Year : 2020
Prescribers : 128
Prescriptions : 558

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Pfizer US Pharm
Talazoparib Tosylate
Drug Cost (USD) : 5,490,082
Year : 2019
Prescribers : 103
Prescriptions : 387

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Company : Pfizer US Pharm
Talazoparib Tosylate
Drug Cost (USD) : 162,688
Year : 2018
Prescribers :
Prescriptions : 11

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Main Therapeutic Indication : Oncology
Currency : USD
2024 Revenue in Millions : 117
2023 Revenue in Millions : 64
Growth (%) : 83

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Market Place
Reply
10 Jan 2023

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : I-920
Exclusivity Expiration Date : 2026-06-20
Application Number : 211651
Product Number : 1
Exclusivity Details :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : I-920
Exclusivity Expiration Date : 2026-06-20
Application Number : 211651
Product Number : 3
Exclusivity Details :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : I-920
Exclusivity Expiration Date : 2026-06-20
Application Number : 211651
Product Number : 5
Exclusivity Details :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : I-920
Exclusivity Expiration Date : 2026-06-20
Application Number : 217439
Product Number : 1
Exclusivity Details :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : I-920
Exclusivity Expiration Date : 2026-06-20
Application Number : 217439
Product Number : 2
Exclusivity Details :

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Exclusivity Code : I-920
Exclusivity Expiration Date : 2026-06-20
Application Number : 217439
Product Number : 4
Exclusivity Details :

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Patent Expiration Date : 2029-07-27
Date Granted : 2017-01-03
Brand Name : TALZENNA
Patent Number : 2732797
Filing Date : 2009-07-27
Strength per Unit : 0.35 mg
Dosage Form : CAPSULE
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2029-07-27
Date Granted : 2017-01-03

Patent Expiration Date : 1931-10-20
Date Granted : 2019-02-12
Brand Name : TALZENNA
Patent Number : 2814581
Filing Date : 2011-10-20
Strength per Unit : 0.35 mg
Dosage Form : CAPSULE
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 1931-10-20
Date Granted : 2019-02-12

Patent Expiration Date : 2029-07-27
Date Granted : 2017-01-03
Brand Name : TALZENNA
Patent Number : 2732797
Filing Date : 2009-07-27
Strength per Unit : 0.5 mg
Dosage Form : CAPSULE
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2029-07-27
Date Granted : 2017-01-03

Patent Expiration Date : 1931-10-20
Date Granted : 2019-02-12
Brand Name : TALZENNA
Patent Number : 2814581
Filing Date : 2011-10-20
Strength per Unit : 0.5 mg
Dosage Form : CAPSULE
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 1931-10-20
Date Granted : 2019-02-12

Patent Expiration Date : 2029-07-27
Date Granted : 2017-01-03
Brand Name : TALZENNA
Patent Number : 2732797
Filing Date : 2009-07-27
Strength per Unit : 0.1 mg
Dosage Form : CAPSULE
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2029-07-27
Date Granted : 2017-01-03

Patent Expiration Date : 1931-10-20
Date Granted : 2019-02-12
Brand Name : TALZENNA
Patent Number : 2814581
Filing Date : 2011-10-20
Strength per Unit : 0.1 mg
Dosage Form : CAPSULE
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 1931-10-20
Date Granted : 2019-02-12

Patent Expiration Date : 2031-10-20
Date Granted : 2019-02-12
Brand Name : TALZENNA
Patent Number : 2814581
Filing Date : 2011-10-20
Strength per Unit : 0.25 mg
Dosage Form : CAPSULE
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2031-10-20
Date Granted : 2019-02-12

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2029-07-27
Date Granted : 2017-01-03
Brand Name : TALZENNA
Patent Number : 2732797
Filing Date : 2009-07-27
Strength per Unit : 0.25 mg
Dosage Form : CAPSULE
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2029-07-27
Date Granted : 2017-01-03

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2031-10-20
Date Granted : 2019-02-12
Brand Name : TALZENNA
Patent Number : 2814581
Filing Date : 2011-10-20
Strength per Unit : 1 mg
Dosage Form : CAPSULE
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2031-10-20
Date Granted : 2019-02-12

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2029-07-27
Date Granted : 2017-01-03
Brand Name : TALZENNA
Patent Number : 2732797
Filing Date : 2009-07-27
Strength per Unit : 1 mg
Dosage Form : CAPSULE
Human Or VET : Human
Route of Administration : ORAL
Patent Expiration Date : 2029-07-27
Date Granted : 2017-01-03

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
32
PharmaCompass offers a list of Talazoparib Tosylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Talazoparib Tosylate manufacturer or Talazoparib Tosylate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Talazoparib Tosylate manufacturer or Talazoparib Tosylate supplier.
A Talazoparib Tosylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Talazoparib Tosylate, including repackagers and relabelers. The FDA regulates Talazoparib Tosylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Talazoparib Tosylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Talazoparib Tosylate supplier is an individual or a company that provides Talazoparib Tosylate active pharmaceutical ingredient (API) or Talazoparib Tosylate finished formulations upon request. The Talazoparib Tosylate suppliers may include Talazoparib Tosylate API manufacturers, exporters, distributors and traders.
Talazoparib Tosylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Talazoparib Tosylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Talazoparib Tosylate GMP manufacturer or Talazoparib Tosylate GMP API supplier for your needs.
A Talazoparib Tosylate CoA (Certificate of Analysis) is a formal document that attests to Talazoparib Tosylate's compliance with Talazoparib Tosylate specifications and serves as a tool for batch-level quality control.
Talazoparib Tosylate CoA mostly includes findings from lab analyses of a specific batch. For each Talazoparib Tosylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Talazoparib Tosylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Talazoparib Tosylate EP), Talazoparib Tosylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Talazoparib Tosylate USP).